Ainos (AIMD) investor relations material

Executive summary

• Focused on commercializing AI Nose, an AI-enabled scent digitization platform, with expansion into semiconductor, robotics, and healthcare infrastructure markets, and advancing VELDONA®, a low-dose oral interferon program, through capital-efficient execution and strategic partnerships.

• Achieved operational milestones transitioning AI Nose from validation to enterprise-level deployment readiness, including deployments in hospital utility systems, laboratory environments, and critical infrastructure safety applications.

• Prioritized Smell ID dataset expansion and Smell Language Model development to support scalable commercialization.

• Shifted strategic focus from healthcare-adjacent applications to industrial deployments, impacting near-term revenue.

Financial highlights

• Q1 2026 revenue was $161, down from $106,207 in Q1 2025, reflecting early-stage commercialization and lower sales volume in healthcare-adjacent programs.

• Net loss for Q1 2026 was $2,459,800, a 25% improvement from $3,286,022 in Q1 2025, driven by reduced operating expenses.

• Operating expenses declined approximately 30% year-over-year to $2.28 million for Q1 2026.

• Cash and cash equivalents increased to $2,841,422 as of March 31, 2026, from $417,353 at year-end 2025.

• Strengthened balance sheet and liquidity with a NT$90 million (approx. $2.8 million) financing arrangement.

Outlook and guidance

• 2026 priorities include expanding industrial deployments of AI Nose, especially in semiconductor and robotics sectors, and managing healthcare programs with a focus on partner-led deployments and data-driven model refinement.

• Anticipates broader revenue generation opportunities in the second half of 2026 as commercialization priorities advance.

• Plans to fund operations over the next twelve months with cash reserves, business revenues, and potential debt or equity financing.

• Substantial doubt exists about the ability to continue as a going concern without additional financing.